Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 106-111

  Weidenbusch, Marc ^a   Römmele, Christoph ^a   Schröttle, Angelika ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

B cell ablation; B cells; glomerulonephritis; lupus nephritis; MabThera; proteinuria; anti CD20; remission; response; systemic lupus erythematosus; therapy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; LUPUS NEPHRITIS; TREATMENT OUTCOME;

EID: 84872224425     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs285     Document Type: Article

References (41)

1. Manger K, Manger B, Repp R et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 1065-1070.
2. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011; 50: 1424-1430.
3. Weening JJ, D'agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
4. Austin HA, 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
5. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
6. Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23: 381-399.
7. Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 2012; 8: 183-189.
8. Lech M, Weidenbusch M, Kulkarni OP et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J Am Soc Nephrol 2011; 22: 1443-1452.
9. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010; 43: 84-97.
10. Chan OT, Hannum LG, Haberman AM et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1648.
11. Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
12. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
13. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012; 64: 1215-1226.
14. Albert D, Dunham J, Khan S et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1724-1731.
15. Arce-Salinas CA, Rodriguez-Garcia F, Gomez-Vargas JI. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int 2011; 32: 1245-1249.
16. Bacconnier L, Combe B, Canaud B et al. Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19. Rheumatology (Oxford) 2010; 49: 2452-2453.
17. Boletis JN, Marinaki S, Skalioti C et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009; 24: 2157-2160.
18. Camous L, Melander C, Vallet M et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008; 52: 346-352.
19. Catapano F, Chaudhry AN, Jones RB et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010; 25: 3586-3592.
20. Chehab G, Sander O, Fischer-Betz R et al. Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus. Z Rheumatol 2007; 66: 330-336.
21. Galarza C, Valencia D, Tobon GJ et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008; 34: 124-128.
22. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010; 19: 213-219.
23. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920.
24. Jonsdottir T, Gunnarsson I, Risselada A et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67: 330-334.
25. Lateef A, Lahiri M, Teng GG et al. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus 2010; 19: 765-770.
26. Li EK, Tam LS, Zhu TY et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 2009; 48: 892-898.
27. Lu TY, Ng KP, Cambridge G et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patients. Arthritis Rheum 2009; 61: 482-487.
28. Mardjuadi A, Soedirman M, Utoyo B et al. Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia. Clin Rheumatol 2009; 28(Suppl 1): S27-S30.
29. Melander C, Sallee M, Trolliet P et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-587.
30. Moroni G, Gallelli B, Banfi G et al. Rituximab monotherapy for remission induction of proliferative lupus nephritis flares: description of 3 cases. J Nephrol 2010; 23: 357-361.
31. Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-3723.
32. Ramos-Casals M, Garcia-Hernandez FJ, De Ramon E et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28: 468-476.
33. Reynolds JA, Toescu V, Yee CS et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 2009; 18: 67-73.
34. Roccatello D, Sciascia S, Rossi D et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011; 26: 3987-3992.
35. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513.
36. Tahir H, Rohrer J, Bhatia A et al. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 2005; 44: 561-562.
37. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and rituximab registry. Arthritis Rheum 2010; 62: 2458-2466.
38. Van Den Bergh B, Selleslag D, Boelaert JR et al. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature. Acta Clin Belg 2005; 60: 102-105.
39. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.
40. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432.
41. Gordon C, Jayne D, Pusey C et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263.